Abstracts tagged "autoimmune diseases"

Abstract Number: 1253 • ACR Convergence 2023
The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease
Akaluck Thatayatikom¹, Wenjie Zeng², Tyler Lovelace³, Nicole Winn⁴, Ankit Shah⁵, Thomas Schrepfer⁶, Indraneel Bhattacharyya⁷, Renato Gonik⁸, Panayiotis Benos² and Seunghee Cha⁹, ¹AdventHealth for Children, Orlando, FL, Orlando, FL, ²University of Florida College of Public Health and Health Professions and College of Medicine, Gainesville, FL, ³Department of Computational & Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Division of Oral Medicine, Department of Oral and Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, ⁵Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL, ⁶Division of Pediatric Otolaryngology, University of Florida College of Medicine, Gainesville, FL, ⁷Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, ⁸Division of Pediatric Neurology, University of Florida College of Medicine, Gainesville, FL, ⁹Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry and Center for Orphaned Autoimmune Disorders (COAD), Gainesville, FL
Background/Purpose: Childhood Sjögren 's disease (cSjD) is a poorly defined systemic autoimmune disorder. Due to the absence of diagnostic criteria, heterogeneous presentations, and the dissimilarity…
Abstract Number: 1530 • ACR Convergence 2023
Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience
Claudia Iannone¹, Maria Rosa Pellico¹, Letizia Corinna Corinna Morlacchi², Valeria Rossetti², Marco Vicenzi², Paolo Airò³, Marta Saracco⁴, Annamaria iagnocco⁴, Lorenzo Beretta⁵, Adriana Severino⁵, Eleonora Zaccara⁶, paola Faggioli⁶, Fabio Cacciapaglia⁷, Stefano Stano⁸, Silvia Cavalli⁹, Antonina Minniti⁹, giorgia Trignani⁹, francesco Blasi⁵, Roberto F. Caporali¹⁰ and Nicoletta Del Papa¹¹, ¹ASST Gaetano Pini CTO, Milan, Italy, ²Policlinico di Milano, Milan, Italy, ³Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, ⁴AO Mauriziano di Torino, Torino, Italy, ⁵Policlinico di Milano, Milano, Italy, ⁶Legnano-ASST-Ovest Milanese, Legnano, Italy, ⁷Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ⁸Policlinico di Bari, Bari, Italy, ⁹ASST Gaetano Pini CTO, Milano, Italy, ¹⁰Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ¹¹Scleroderma Clinic, Dipartimento di Reumatologia, ASST Gaetano Pini CTO, Milano, Italy
Background/Purpose: Lung transplantation (LT) is gaining ground in managing advanced ILD in SSc patients. However, concerns remain among surgeons due to SSc's complexity, multiorgan involvement…
Abstract Number: 1720 • ACR Convergence 2023
Successful Treatment of Rheumatoid Arthritis in Mice Using Cenerimod, a Selective Modulator of the S1P1 Receptor, Demonstrates the Potential Benefits of S1P1 Receptor Immunomodulation for Rheumatic Diseases
Thomas Hoyler, Maxime Bulle, Conrad Wyss, Jeremy Scherer, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Discovery of the essential role of S1P signaling in regulating lymphocyte trafficking led to the development of S1P receptor modulators for the treatment of…
Abstract Number: 1914 • ACR Convergence 2023
Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes
Cristina Corrales Selaya¹, David Martínez-Lopez², Diana Prieto-Peña¹, Fabricio Benavides¹, Jose Luis Martin-Varillas³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterised mainly by the presence of inflammation and muscle weakness. The main subtypes of…
Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
COMFORT ANIM-KORANTENG¹, YONG EUN², Okeoghene Akpoigbe² and AMANDA SAMMUT², ¹Harlem Hospital Center, New York, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
Abstract Number: 2350 • ACR Convergence 2023
Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303; TACI vTD-Fc)
Tiffany Blair, Elizabeth Repash, Armand Bankhead, Amanda Enstrom, Lawrence Evans, Susan Debrot, Allison Chunyk, Sherri Mudri, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are cytokines that signal through transmembrane activator and CAML interactor (TACI), B cell maturation…
Abstract Number: 2536 • ACR Convergence 2023
DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA
Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
Abstract Number: 0074 • ACR Convergence 2023
Distinct PD-1 Receptor Engagement Leads to Different Pharmacodynamic Effects
Yevgeniya Orlovsky, Melissa Swiecki, Kimberly Colby, Changbao Liu, Josephine Wixted, Olesya Chornoguz, Navin Rao, Edith Janssen and Ling-Yang Hao, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: T cells play an important role in the development and progression of many autoimmune diseases. Inhibition of T cells and their effector mechanisms has…
Abstract Number: 0197 • ACR Convergence 2023
Development of a Chikungunya Arthritis Disease Activity Score
Aileen Chang¹, Samuel Simmens¹, Hugh Watson², Richard Amdur³, Andre Siqueira⁴, Abigale Proctor¹, Sarah Tritsch¹, Carlos Herrera¹, Liliana Encinales⁵, Alfonso Sucerquia¹, Alejandro Jaller¹, Juan Jose Jaller⁶, Kennedy Amaral⁷, Gary Simon¹, Larry Moreland⁸, Andres Cadena⁹ and Gary Firestein¹⁰, ¹George Washington University, Washington, DC, ²Evotec, Lyon, France, ³Northwell, Washington, DC, ⁴Fiocruz, Rio, Brazil, ⁵Allied Research Society, Barranquilla, Colombia, ⁶Reumatologos SAS, Barranquilla, Colombia, ⁷Institute of Diagnostic Medicine of Cariri, Pernambuco, Brazil, ⁸University of Colorado, Denver, CO, ⁹Clinica de la Costa, Barranquilla, Colombia, ¹⁰University of California San Diego, San Diego, CA
Background/Purpose: Chikungunya virus is an alphavirus spread by mosquitos that causes a debilitating chronic arthritis that has no standard treatment to date. The objective of…
Abstract Number: 0274 • ACR Convergence 2023
A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab
Nathalie Amiable¹, Mehdi Benlarbi², Mathieu Dube³, Sonia Theriault⁴, Alexandra Godbout¹, Anne-Sophie Julien⁵, Gloria-Gabrielle Ortega-Delgado⁶, Melina Duchesne⁷, Rose Cloutier⁸, Josee Perreault⁹, Annie Gravel¹⁰, Lison Fournier¹¹, Giuliana Alfonso¹², Josiane Bourre-Tessier¹³, Marie Hudson¹⁴, Nicolas Richard¹⁵, Jean-Paul Makhzoum¹⁶, Arielle Mendel¹⁷, Sasha Bernatsky¹², Marc Dionne¹⁸, Michael Libman¹⁹, Gaston De Serres²⁰, Mélanie Dieudé²¹, louis Flamand²², Daniel Kaufmann²³, Andrés Finzi²⁴, Renée Bazin²⁵, Ines Colmegna²⁶ and Paul R. Fortin²⁷, ¹Centre ARThrite - CHU de Quebec - Universite Laval, Quebec City, QC, Canada, ²CRCHUM, Université de Montréal, Montreal, QC, Canada, ³Centre de recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁶Centre de Recherche du CHUM, Montreal, QC, Canada, ⁷Centre de recherche du Centre Hospitalier de l'Universitaire de Montréal, Montreal, QC, Canada, ⁸Centre de recherche hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁹Hema-Quebec, Quebec City, QC, Canada, ¹⁰CHU de Québec - CHUL Axe des Maladies Infectieuses et Immunitaires, Quebec City, QC, Canada, ¹¹Centre de recherche du CHU de Quebec - Université Laval, Quebec City, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ¹⁴McGill University, Montréal, QC, Canada, ¹⁵Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁶Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹⁷McGill University Health Centre, Montréal, QC, Canada, ¹⁸Centre de recherche du CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁹McGill Centre for Viral Diseases, Montreal, QC, Canada, ²⁰Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ²¹Microbiology, Infectiology and Immunology Department, Faculty of Medicine, Université de Montréal, CHUM Research Center, Héma-Québec, Montreal, QC, Canada, ²²Centre ARThrite - CHU de Quebec - Université Laval, Quebec City, QC, Canada, ²³University of Montreal, University of Lausanne, Lausanne University Hospital, Montreal, QC, Canada, ²⁴Université de Montréal, Montreal, QC, Canada, ²⁵Héma-Québec, Affaires Médicales et Innovation, Quebec City, QC, Canada, ²⁶The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada
Background/Purpose: Patients with rheumatic diseases (RD) on rituximab (RTX) have increased mortality following COVID-19 and reduced antibody response post-vaccine. We tested whether a mix-and-match strategy…
Abstract Number: 0487 • ACR Convergence 2023
A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis
Ashmia Saif¹, Priyanka Dongare², Meghan Beard³, Yunhan Liao⁴, Xiaoyue Zhang⁴, Qingping Yao⁵ and Asha Patnaik⁶, ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University Hospital, Highland, NY, ³Stony Brook Southampton, Moriches, NY, ⁴Biostatistical Consulting Core - Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, ⁵Stony Brook University, Stony Brook, NY, ⁶Stony Brook University Medical Center, East Setauket, NY
Background/Purpose: Autoimmune diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) can causes erositis including pericarditis and pleuritis. However, the rate of serositis in…
Abstract Number: 0722 • ACR Convergence 2023
Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Rashmi Dhital¹, Rebecca Baer², Monica Guma², Kenneth Kalunian², Accelerating Medicines Partnership Program RA SLE Network³ and Christina Chambers², ¹UC San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome…
Abstract Number: 0951 • ACR Convergence 2023
Single Cell Analysis of Transitional B Cells in Systemic Sclerosis Highlights Defective Peripheral Tolerance
Claire Beesley¹, Nina Goldman¹, David Abraham¹, Christopher Denton¹, Rizgar Mageed² and Voon Ong³, ¹University College London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Transitional B cells comprise a distinct population of B cells that have recently migrated to the periphery from the bone marrow. In systemic sclerosis…
Abstract Number: 1075 • ACR Convergence 2023
Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Lourdes Gonzalez Arreola¹, Carrie Ye², Marie Hudson³, Janet Roberts⁴, Janet Pope⁵, Thomas Appleton⁵, Sabrina Hoa⁶, Aurore Fifi-Mah⁷, Nancy Maltez⁸, Alexandra Saltman⁹, Megan Himmel⁹, Ines Colmegna¹⁰, Alexandra Ladouceur¹¹, Anthony Obrzut¹, Jeremiah Tan¹², David Moon², Tatiana Nevskaya⁵, Emma Schmidt¹³, Lindsay Cho⁴, Nader Toban¹⁴ and Shahin Jamal¹⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada, ³McGill University, Montréal, QC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Ottawa Hospital, Ottawa, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ¹²Arthritis Research Canada, Vancouver, Canada, Vancouver, BC, Canada, ¹³University of British Columbia, Vancouver, BC, Canada, ¹⁴Centre Hospitalier de l'Université de Montréal, Dollard-des-Ormeaux, QC, Canada, ¹⁵Vancouver Coastal Health, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of treatment for many cancers. However, most cancer clinical trials for ICI excluded patients with pre-existing…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].